Capricor hits 2-yr low after FDA panel votes against Duchenne therapy
BUZZ-Capricor hits 2-yr low after FDA panel votes against Duchenne therapy Updates
** Shares of drug developer Capricor Therapeutics CAPR.O fall 50% to $3.27
** Shares hit a more than two-year low and are down about 92% from their 52-week high of $40.37 reached in Dec 2025
** The U.S. FDA's panel of independent advisers voted 9-3 against Capricor's cell therapy, deramiocel, citing a lack of convincing evidence of benefit in Duchenne-related heart disease
** FDA staff raised concerns that Capricor changed key statistical analyses after the study was completed
** Cantor Fitzgerald analysts' says the FDA's tone was "extremely negative" and sees an "unlikely path forward" for deramiocel
** Capricor shares plunged roughly 83%, from Friday's close of $19.70 to Thursday's $3.27, since FDA released briefing documents on Monday
** More than 14.3 mln shares traded, about 4.5 times the stock's 30-day avg volume
** The FDA is expected to decide on the therapy by Aug. 22, though it is not bound by the panel's recommendation
Including session's move, stock down 88.7% YTD
(Reporting by Kamal Choudhury in Bengaluru)